Bedrijfsoverzicht
Establishment Labs Holdings Inc. is a medical technology enterprise dedicated to the manufacture and distribution of medical devices specifically designed for breast aesthetic and reconstructive plastic surgeries. The company operates within the healthcare sector, focusing on the medical devices industry which serves a global market spanning Europe, the Middle East, Africa, Latin America, Asia, and the United States. This entity has established a significant operational scale, evidenced by a market capitalization of $1.76 billion and an annual revenue of $211.08 million over the trailing twelve months. Furthermore, the organization employs a workforce of 1004 individuals, reflecting a substantial infrastructure required to support its international manufacturing and marketing activities. The valuation metrics indicate that the market assigns a high premium to the company's intellectual property and device portfolio, suggesting strong investor confidence in its technological moat despite the current lack of profitability. The revenue figure of $211.08 million places the company among the larger players in its niche, while the employee count of 1004 demonstrates the extensive logistical and sales networks necessary to penetrate diverse geographic markets effectively.
Financiële gezondheid
The company reported total revenue of $211.08 million for the trailing twelve months, yet this generated a net income of -$51,064,000 and an EBITDA of -$29,445,000. The substantial gap between the revenue figure and the negative net income reveals a cost structure where operating expenses significantly exceed gross profits, a common characteristic during periods of rapid expansion or heavy research and development investment. Free cash flow stands at -$41,574,000, indicating that the company's capital expenditures and working capital requirements currently outpace its cash generation from operations. This negative cash flow position implies limited financial flexibility for discretionary spending, forcing management to prioritize capital preservation over aggressive expansion initiatives in the near term. Margin analysis shows a gross margin of 69.3%, which indicates strong pricing power or high-quality manufacturing efficiency at the production level. However, the operating margin of -6.1% and profit margin of -24.2% highlight that high fixed costs and selling, general, and administrative expenses are eroding the value created by the core product. The balance sheet presents a leveraged profile with total debt of $264.47 million against cash holdings of $75.57 million, resulting in a debt-to-equity ratio of 1123.14. This high leverage ratio suggests the company is utilizing significant borrowed capital, which increases financial risk but may also amplify potential returns once profitability is restored. Liquidity is robust, as indicated by a current ratio of 3.04, meaning the company holds more than three times the assets required to cover its short-term liabilities. Finally, the return on equity is -133.3% and the return on assets is -6.9%, metrics that reveal that management is currently destroying shareholder value rather than generating returns on the capital deployed.
Waarderingsbeoordeling
Valuation multiples for Establishment Labs reflect the high risk associated with unprofitable growth, with a forward P/E of 293.61 while the trailing P/E is N/A due to negative earnings. The absence of a trailing P/E and the extremely high forward P/E imply that the market is pricing in a significant turnaround or earnings recovery trajectory that has not yet materialized in historical data. The price-to-book ratio stands at 74.86, indicating that the market values the company at more than 74 times its book value, which suggests a heavy premium assigned to intangible assets or future growth potential. Additionally, the price-to-sales ratio of 8.36 and the EV/EBITDA of -66.35 provide alternative perspectives on valuation that are sensitive to the lack of current earnings, highlighting the speculative nature of the current share price. Price action over the last year shows a 52-week high of $83.31 and a 52-week low of $28.67, with the current trading price situated near the lower end of this volatility range relative to the recent peak. The stock exhibits a beta of 1.08, which means its price volatility is slightly higher than the broader market, moving 8% more than the market index in response to general market fluctuations. These metrics collectively suggest that the stock is sensitive to market sentiment and interest rate changes, particularly given the negative earnings backdrop that distorts traditional valuation multiples.
Growth & Income
Revenue growth for the trailing twelve months stands at 45.2%, demonstrating a robust expansion in sales volume or pricing, whereas earnings growth is N/A because the company remains in a loss position. The divergence between strong revenue growth and negative earnings growth implies that top-line expansion is occurring at a pace faster than cost reductions can occur, a typical phase in the lifecycle of a high-growth medical device manufacturer. As the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, indicating that the firm reinvests all available cash flow back into the business rather than distributing income to shareholders. This reinvestment strategy is necessary to fund the high operating expenses and debt obligations required to sustain the rapid revenue growth observed in the current fiscal period. The overall growth and income profile is characterized by aggressive sales expansion that is not yet supported by bottom-line profitability, resulting in a financial structure that relies on future earnings recovery to justify current valuations.